EMEA-001579-PIP01-13-M05
Key facts
| Invented name |
Truberzi
|
| Active substance |
Eluxadoline
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0128/2022
|
| PIP number |
EMEA-001579-PIP01-13-M05
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of diarrhoea-predominant irritable bowel Syndrome
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AbbVie Ltd
E-mail: paediatricteam@abbvie.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|